Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemoradiotherapy in high-risk locally advanced nasopharyngeal carcinoma
ChiCTR2400084683Phase 2Not yet recruiting
- Sponsor
- Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital. Primary endpoints: Complete Response Rate and Safety. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400084683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084683.